6-(tert-butyl)thiochromane | 15084-69-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 硫铬烷
• 英文名称: 6-(tert-butyl)thiochromane
• 英文别名: 6-(1,1-Dimethylethyl)-3,4-dihydro-2H-1-benzothiopyran；6-tert-butyl-3,4-dihydro-2H-thiochromene
• CAS: 15084-69-2
• 化学式: C₁₃H₁₈S
• 分子量: 206.352
• InChiKey: ZOEJVCIGSQZDRF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  25.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  6-tert-butyl-2,3-dihydro-4H-1-benzothiopyran-4-one 在 三乙基硅烷 、 三氟乙酸 作用下， 反应 2.0h， 以63%的产率得到6-(tert-butyl)thiochromane
  参考文献：
  名称：

  硫醚配体活化的阳离子钯（II）催化α，β-不饱和肟醚的亲电CH芳基化反应。

  摘要：

  阳离子钯（II）催化剂的使用实现了α，β-不饱和O - SEM肟与芳基硼酸的亲电C–H芳基化。通过使用烷基芳基硫醚配体可以促进这种Pd催化的亲电C–H芳基化，配体结构的优化大大提高了收率。所得的α，β-不饱和肟将提供多取代杂环化合物的获得。

  DOI：

  10.1021/acs.joc.0c01570

文献信息

• METHOD FOR PRODUCING INTERMEDIATE USEFUL FOR SYNTHESIS OF SGLT INHIBITOR
  申请人：Daewoong Pharmaceutical Co., Ltd.

  公开号：US20210292291A1

  公开（公告）日：2021-09-23

  A method of preparing an intermediate useful for the synthesis of a diphenylmethane derivative that can be used as an SGLT inhibitor is described. A method of synthesizing a compound of Formula 7 can address problems of existing synthesis processes requiring the synthesis of the Grignard reagent and management of related substances. In addition, the method can minimize the generation of related substances, and thus does not require reprocessing of reaction products, thereby simplifying the process. Accordingly, the production yield of a diphenylmethane derivative can be maximized.

  描述了一种用于合成可用作SGLT抑制剂的二苯甲烷衍生物的中间体的制备方法。合成化合物7的方法可以解决现有合成过程中需要合成格氏试剂并管理相关物质的问题。此外，该方法可以最小化相关物质的生成，因此不需要对反应产物进行再处理，从而简化了过程。因此，可以最大化二苯甲烷衍生物的产量。
• C-ARYL GLUCOSIDE DERIVATIVE, PREPARATION METHODS THEREOF, AND MEDICAL APPLICATIONS THEREOF
  申请人：JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.

  公开号：US20160222047A1

  公开（公告）日：2016-08-04

  C-aryl glucoside derivatives, preparation methods thereof, and medical applications thereof are described. Specifically, compounds represented by formula I, and, tautomers, enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts of the compounds, preparation methods thereof, pharmaceutical compositions containing the compounds, and applications thereof are described. Compounds of formula (I) are useful as therapeutic agents, and particularly as sodium-dependent glucose contransporter protein (SGLT) inhibitors.

  本文描述了C-芳基葡萄糖苷衍生物，其制备方法以及医药应用。具体而言，描述了由式I表示的化合物，以及该化合物的互变异构体、对映体、非对映体、拉卡酯和药学上可接受的盐，其制备方法，含有该化合物的药物组合物以及其应用。式(I)的化合物可用作治疗剂，特别是作为钠依赖葡萄糖共转运蛋白（SGLT）抑制剂。
• METHOD FOR PRODUCING DIPHENYLMETHANE DERIVATIVE
  申请人：DAEWOONG PHARMACEUTICAL CO., LTD.

  公开号：US20190169174A1

  公开（公告）日：2019-06-06

  The present invention relates to an improved method for producing a diphenylmethane derivative which is effective as a sodium-dependent glucose cotransporter (SGLT) inhibitor, the method being carried out by means of a convergent synthesis method in which each major group is separately synthesized and then coupled. As such, in comparison to a linear synthesis method disclosed in existing documents, the synthesis pathway is compact and yield can be increased, and risk factors inherent in the linear synthesis pathway can be reduced. Furthermore, the crystal form of the compound produced according to the method has superb physicochemical characteristics, and thus can be effectively utilized in fields such as pharmaceutical manufacturing.

  本发明涉及一种改进的制备二苯甲烷衍生物的方法，该方法作为一种钠依赖型葡萄糖共转运蛋白（SGLT）抑制剂具有高效性，该方法通过收敛合成方法进行，其中每个主要基团分别合成然后耦合。因此，与现有文件披露的线性合成方法相比，合成途径更为紧凑，产率可以提高，并且线性合成途径固有的风险因素可以降低。此外，根据该方法生产的化合物的晶型具有出色的物理化学特性，因此可以有效地应用于制药制造等领域。
• Direct Access to S-Heterocycles by Scandium(III) Triflate Catalyzed Cyclization of Aromatic Thiols and Diols
  作者：Maki Minakawa、Keisuke Minami、Yuya Sato

  DOI：10.1055/s-0040-1720350

  日期：2021.11

  A simple and environmentally friendly method to prepare S-heterocycles by cyclization of aromatic thiols and diols with H2O as a byproduct is described. The Sc(OTf)3-catalyzed dehydrative cyclizations of aromatic thiols and diols provided the corresponding thiopyran and thiophene derivatives. Control experiments were also performed to obtain insights into the reaction pathway

  摘要：描述了一种简单且环保的方法，通过芳香硫醇和二醇的环化反应制备S-杂环化合物，副产物为H2O。Sc(OTf)3催化的芳香硫醇和二醇的脱水环化反应提供了相应的硫吡喃和硫吲哚衍生物。还进行了对照实验，以深入了解反应途径。
• TRICYCLIC ANTIBIOTICS
  申请人：Gaucher Bérangère

  公开号：US20120245345A1

  公开（公告）日：2012-09-27

  Compound of formula (I): wherein A1 represents —O—, —S— or —N—R3; A2 represents —CH 2 —, —O—, —N—R4, —C(═O)— or —CH(O—R4)—; A3 represents C 3 -C 8 cycloalkylene; saturated and unsaturated 4 to 8-membered heterocyclodiyl with 1, 2 or 3 heteroatoms selected from nitrogen, oxygen and sulphur, which group A3 is unsubstituted or substituted; A4 represents C 1 -C 4 alkylene, C 2 -C 4 alkenylene, >C═O or a group selected from —C 2 H 4 NH—, —C 2 H 4 O—, and —C 2 H 4 S— being linked to the adjacent NR5-group via the carbon atom; and G represents aryl or heteroaryl, which is un-substituted or substituted and R1 and R2 independently of one another, represent hydrogen or a substituent selected from hydroxy, halogen, mercapto, cyano, nitro, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, C 1 -C 6 alkylcarbonyloxy, C 1 -C 6 alkylsulfonyloxy, C 1 -C 6 heteroalkylcarbonyloxy, C5-C 6 heterocyclylcarbonyloxy, C 1 -C 6 heteroalkoxy, wherein heteroalkyl, heteroalkoxy groups or heterocyclyl comprise 1, 2 or 3 heteroatoms selected from nitrogen, oxygen and sulphur, in which substituents the alkyl moieties are unsubstituted or further substituted; R3, R4 and R5 independently of one another, represent hydrogen or C 1 -C 6 alkyl; X1 and X2 independently of one another, represent a nitrogen atom or CR2, with the proviso that at least one of X1 and X2 represents a nitrogen atom; m is 1; and the (CH2)m moiety is optionally substituted by C 1 -C 4 alkyl; halogen, carboxy, hydroxy, C 1 -C 4 alkoxy, C 1 -C 4 -alkylcarbonyloxy, amino, mono- or di-(C 1 -C 4 alkyl)amino or acylamino n is 0, 1 or 2 or pharmaceutically acceptable salt thereof are valuable for use as a medicament for the treatment of bacterial infections.

  化合物的公式（I）：其中A1代表—O—、—S—或—N—R3；A2代表—CH2—、—O—、—N—R4、—C（═O）—或—CH（O—R4）—；A3代表C3-C8环烷基、饱和和不饱和的4至8元杂环二基，其中1、2或3个杂原子选自氮、氧和硫，该基团A3未取代或取代；A4代表C1-C4烷基、C2-C4烯基、>C═O或从—C2H4NH—、—C2H4O—和—C2H4S—中选择的基团，通过碳原子与相邻的NR5基团连接；G代表芳基或杂芳基，未取代或取代，R1和R2独立地代表氢或来自羟基、卤素、硫醇基、氰基、硝基、C1-C6烷基、C1-C6烷氧基、C1-C6烷硫氧基、C1-C6烷基羰酸酯氧基、C1-C6烷基磺酸酯氧基、C1-C6杂烷基羰酸酯氧基、C5-C6杂环烷基羰酸酯氧基、C1-C6杂烷氧基，其中杂烷基、杂烷氧基或杂环烷基包含1、2或3个选自氮、氧和硫的杂原子，在这些取代基中，烷基基团未取代或进一步取代；R3、R4和R5独立地代表氢或C1-C6烷基；X1和X2独立地代表氮原子或CR2，但至少其中之一代表氮原子；m为1；（CH2）m基团可选择地被C1-C4烷基、卤素、羧基、羟基、C1-C4烷氧基、C1-C4烷基羰酸酯氧基、氨基、单或双-(C1-C4烷基)氨基或酰胺基取代；n为0、1或2或其药学上可接受的盐，用作治疗细菌感染的药物。